Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Biochemical and Biophysical Research Communications

Volumn 366, Issue 3, 2008, Pages 848-851

  Gupta, Manu ^a   Milani, Lili ^a   Hermansson, Monica ^b   Simonsson, Bengt ^b   Markevärn, Berit ^c   Syvänen, Ann Christine ^a   Barbany, Gisela ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BCR ABL1 expression; Disease progression; Imbalanced allelic expression; Oncogene; Quantitative SNP assay

Indexed keywords

IMATINIB;

ADULT; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; FEMALE; GENE EXPRESSION; GENE FUSION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; MALE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 37549027671     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.12.029     Document Type: Article

References (14)

1. Melo J.V., and Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7 (2007) 441-453
2. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
3. Barnes D.J., Schultheis B., Adedeji S., and Melo J.V. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24 (2005) 6432-6440
4. Gaiger A., Henn T., Horth E., Geissler K., Mitterbauer G., Maier-Dobersberger T., Greinix H., Mannhalter C., Haas O.A., Lechner K., and Lion T. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86 (1995) 2371-2378
5. Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E., Ben-Neriah Y., and Ben-Yehuda D. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94 (1999) 2452-2460
6. Liljedahl U., Fredriksson M., Dahlgren A., and Syvanen A.C. Detecting imbalanced expression of SNP alleles by minisequencing on microarrays. BMC Biotechnol. 4 (2004) 24
7. Barbany G., Hoglund M., and Simonsson B. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N. Engl. J. Med. 347 (2002) 539-540
8. Fredriksson M., Barbany G., Liljedahl U., Hermanson M., Kataja M., and Syvanen A.C. Assessing hematopoietic chimerism after allogeneic stem cell transplantation by multiplexed SNP genotyping using microarrays and quantitative analysis of SNP alleles. Leukemia 18 (2004) 255-266
9. Thorn I., Olsson-Stromberg U., Ohlsen C., Jonsson A.M., Klangby U., Simonsson B., and Barbany G. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 90 (2005) 1471-1476
10. Crossman L.C., O'Hare T., Lange T., Willis S.G., Stoffregen E.P., Corbin A.S., O'Brien S.G., Heinrich M.C., Druker B.J., Middleton P.G., and Deininger M.W. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia 19 (2005) 1859-1862
11. Nicolini F.E., Chabane K., Cayuela J.M., Rousselot P., Thomas X., and Hayette S. The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib. Haematologica 91 (2006) 137-138
12. Zion M., Ben-Yehuda D., Avraham A., Cohen O., Wetzler M., Melloul D., and Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA 91 (1994) 10722-10726
13. Wang J.Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 19 (2000) 5643-5650
14. Boultwood J., and Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br. J. Haematol. 138 (2007) 3-11